These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32152818)

  • 1. Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct
    Bjørnsdottir I; Støvring B; Søeborg T; Jacobsen H; Sternebring O
    Drugs R D; 2020 Jun; 20(2):75-82. PubMed ID: 32152818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
    Agersø H; Stennicke HR; Pelzer H; Olsen EN; Merricks EP; Defriess NA; Nichols TC; Ezban M
    Haemophilia; 2012 Nov; 18(6):941-7. PubMed ID: 22812621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of turoctocog alfa pegol (N8-GP; ESPEROCT
    Ezban M; Hansen M; Kjalke M
    Haemophilia; 2020 Jan; 26(1):156-163. PubMed ID: 31809565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
    Pickering W; Hansen M; Kjalke M; Ezban M
    J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring factor VIII activity in samples from patients treated with N8-GP (Esperoct
    Møss J; Clausen WHO; Ezban M
    Haemophilia; 2021 May; 27(3):e389-e392. PubMed ID: 33314455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the pathfinder clinical trials program: Long-term efficacy and safety of N8-GP in patients with hemophilia A.
    Matsushita T; Mangles S
    J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):26-33. PubMed ID: 32558236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cases of less-than-expected FVIII activity in previously treated patients during post-marketing surveillance of N8-GP.
    Oldenburg J; Benson G; Chowdary P; Halimeh S; Matsushita T; Nørland A; Wahid MN; Nemes L
    Haemophilia; 2023 Nov; 29(6):1475-1482. PubMed ID: 37729439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.
    Giangrande P; Abdul Karim F; Nemes L; You CW; Landorph A; Geybels MS; Curry N
    J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):5-14. PubMed ID: 32544297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
    Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
    Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
    Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
    Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
    Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5.
    Šaulytė Trakymienė S; Economou M; Kenet G; Landorph A; Shen C; Kearney S
    J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):15-25. PubMed ID: 32940955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience.
    Hegemann I; Koch K; Clausen WHO; Ezban M; Brand-Staufer B
    Acta Haematol; 2020; 143(5):504-508. PubMed ID: 31639805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
    Klamroth R; Feistritzer C; Friedrich U; Lentz SR; Reichwald K; Zak M; Chowdary P
    J Thromb Haemost; 2020 Feb; 18(2):341-351. PubMed ID: 31618804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP).
    Klamroth R; Hampton K; Saulyte Trakymienė S; Korsholm L; Carcao M
    Patient Prefer Adherence; 2021; 15():2443-2454. PubMed ID: 34764641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
    Male C; Königs C; Dey S; Matsushita T; Millner AH; Zak M; Young G; Kenet G
    Blood Adv; 2023 Feb; 7(4):620-629. PubMed ID: 35858373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.
    Stennicke HR; Kjalke M; Karpf DM; Balling KW; Johansen PB; Elm T; Øvlisen K; Möller F; Holmberg HL; Gudme CN; Persson E; Hilden I; Pelzer H; Rahbek-Nielsen H; Jespersgaard C; Bogsnes A; Pedersen AA; Kristensen AK; Peschke B; Kappers W; Rode F; Thim L; Tranholm M; Ezban M; Olsen EH; Bjørn SE
    Blood; 2013 Mar; 121(11):2108-16. PubMed ID: 23335368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
    Tiede A; Brand B; Fischer R; Kavakli K; Lentz SR; Matsushita T; Rea C; Knobe K; Viuff D
    J Thromb Haemost; 2013 Apr; 11(4):670-8. PubMed ID: 23398640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.